Fmr LLC Boosts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Fmr LLC lifted its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 166.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,649 shares of the biotechnology company’s stock after buying an additional 1,656 shares during the period. Fmr LLC’s holdings in REGENXBIO were worth $28,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in REGENXBIO by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after purchasing an additional 37,055 shares during the period. Intech Investment Management LLC bought a new position in shares of REGENXBIO during the third quarter valued at approximately $161,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of REGENXBIO in the 3rd quarter worth approximately $643,000. Sigma Planning Corp increased its position in REGENXBIO by 17.5% during the 3rd quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 5,701 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in REGENXBIO by 48.5% in the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 11,784 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 46.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 13.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RGNX shares. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 target price on shares of REGENXBIO in a research report on Wednesday, December 11th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. HC Wainwright decreased their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Performance

NASDAQ RGNX opened at $7.40 on Thursday. The stock has a market cap of $366.63 million, a price-to-earnings ratio of -1.47 and a beta of 1.24. REGENXBIO Inc. has a twelve month low of $7.15 and a twelve month high of $28.80. The firm’s 50 day moving average price is $9.40 and its two-hundred day moving average price is $11.03.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.